Anthrax as a biological weapon: Medical and public health management

JAMA

Volumn 281, Issue 18, 1999, Pages 1735-1745

  Inglesby, Thomas V ^a,b   Henderson, Donald A ^a   Bartlett, John G ^a,b   Ascher, Michael S ^c   Eitzen, Edward ^d   Friedlander, Arthur M ^d   Hauer, Jerome ^e   McDade, Joseph ^f   Osterholm, Michael T ^g   O'Toole, Tara ^a   Parker, Gerald ^d   Perl, Trish M ^a,b   Russell, Philip K ^a   Tonat, Kevin ^h  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c California Department of Public Health   (United States)

^d UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

^e Office of Emergency Management   (United States)

^f CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^g MINNESOTA DEPARTMENT OF HEALTH   (United States)

^h U S DEPARTMENT OF HEALTH AND HUMAN SERVICES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LIVE VACCINE;

ANTHRAX; BACILLUS ANTHRACIS; BIOLOGICAL WARFARE; DATA BASE; HEALTH CARE MANAGEMENT; HUMAN; INFECTION CONTROL; MEDICAL INFORMATION; PRIORITY JOURNAL; PROPHYLAXIS; PUBLIC HEALTH; REVIEW; VACCINATION;

EID: 0033549124     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.281.18.1735     Document Type: Review

References (73)

1. Carter A, Deutsch J, Zelicow P. Catastrophic terrorism. Foreign Aff. 1998;77:80-95.
2. Lew D. Bacillus anthracis (anthrax). In: Mandell GL, Bennett JE, Dolin R, eds. Principles and Practices of Infectious Disease. New York, NY: Churchill Livingstone Inc; 1995:1885-1889.
3. Christopher GW, Cieslak TJ, Pavlin JA, Eitzen EM. Biological warfare: a historical perspective. JAMA. 1997; 278:412-417.
4. Cole LA. The specter of biological weapons. Sci Am. December 1996:60-65.
5. Zilinskas RA. Iraq's biological weapons: the past as future? JAMA. 1997;278:418-424.
6. Public Health Service Office of Emergency Preparedness. Proceedings of the Seminar on Responding to the Consequences of Chemical and Biological Terrorism. Washington, DC: US Dept of Health and Human Services; 1995.
7. WuDunn S, Miller J, Broad W. How Japan germ terror alerted world. New York Times. May 26, 1998:1-6.
8. Meselson M, Guillemin J, Hugh-Jones M, et al. The Sverdlovsk anthrax outbreak of 1979. Science. 1994; 266:1202-1208.
9. World Health Organization. Health Aspects of Chemical and Biological Weapons. Geneva, Switzerland: World Health Organization; 1970:98-99.
10. Simon JD. Biological terrorism: preparing to meet the threat. JAMA. 1997;278:428-430.
11. Cristy GA, Chester CV. Emergency Protection Against Aerosols. Oak Ridge, Tenn: Oak Ridge National Laboratory; 1981. Publication ORNL-5519.
12. Office of Technology Assessment, US Congress. Proliferation of Weapons of Mass Destruction. Washington, DC: US Government Printing Office; 1993: 53-55. Publication OTA-ISC-559.
13. Kaufmann AF, Meltzer MI, Schmid GP. The economic impact of a bioterrorist attack. Emerg Infect Dis. 1997;3:83-94.
14. Kohout E, Sehat A, Ashraf M. Anthrax: a continuous problem in south west Iran. Am J Med Sci. 1964;247:565.
15. Pienaar UV. Epidemiology of anthrax in wild animals and the control on anthrax epizootics in the Kruger National Park, South Africa. Fed Proc. 1967;26:1496-1591.
16. Dragon DC, Rennie RP. The ecology of anthrax spores. Can Vet J. 1995;36:295-301.
17. Titball RW, Tumbull PC, Hutson RA. The monitoring and detection of Bacillus anthracis in the environment. J Appl Bacteriol. 1991;70(suppl):9S-18S.
18. Brachman PS, Friedlander A. Anthrax. In: Plotkin SA, Orenstein WA, eds. Vaccines. 3rd ed. Philadelphia, Pa: WB Saunders Co; 1999:629-637.
19. Brachman PS. Inhalation anthrax. Ann N Y Acad Sci. 1980;353:83-93.
20. Centers for Disease Control and Prevention. Summary of notifiable diseases, 1945-1994. MMWR Morb Mortal Wkly Rep. 1994;43:70-78.
21. Myenye KS, Siziya S, Peterson D. Factors associated with human anthrax outbreak in the Chikupo and Ngandu villages of Murewa district in Mashonaland East Province, Zimbabwe. Cent Afr J Med. 1996;42: 312-315.
22. Tekin A, Bulut N, Unal T. Acute abdomen due to anthrax. Br J Surg. 1997;84:813.
23. Friedlander A. Anthrax. In: Zajtchuk R, Bellamy RF, eds. Textbook of Military Medicine: Medical Aspects of Chemical and Biological Warfare. Washington, DC: Office of the Surgeon General, US Dept of the Army; 1997:467-478.
24. Sirisanthana T, Nelson KE, Ezzell JW, Abshire TG. Serological studies of patients with cutaneous and oralpharyngeal anthrax from northern Thailand. Am J Trop Med Hyg. 1988;39:575-581.
25. Kunanusont C, Limpakarnjanarat K, Foy HM. Outbreak of anthrax in Thailand. Ann Trop Med Parasitol. 1989;84:507-512.
26. Sirisanthana T, Navachareon N, Tharavichitkul P, Sirisanthana V, Brown AE. Outbreak of oralpharyngeal anthrax. Am J Trop Med Hyg. 1984;33: 144-150.
27. Dutz W, Saidi F, Kouhout E. Gastric anthrax with massive ascites. Gut. 1970;11:352-354.
28. Friedlander A, Welkos SL, Pitt ML, et al. Postexposure prophylaxis against experimental inhalation anthrax. J Infect Dis. 1993;167:1239-1242.
29. Lincoln RE, Hodges DR, Klein F, et al. Role of the lymphatics in the pathogenesis of anthrax. J Infect Dis. 1965;115:481-494.
30. Williams RP. Bacillus anthracis and other spore forming bacilli. In: Braude Al, Davis LE, Fierer J, eds. Infectious Disease and Medical Microbiology. Philadelphia, Pa: WB Saunders Co; 1986:270-278.
31. Druett HA, Henderson DW, Packman L, Peacock S. Studies on respiratory infection. J Hyg. 1953; 51:359-371.
32. Hatch TF. Distribution and deposition of inhaled particles in respiratory tract. Bacteriol Rev. 1961;25: 237-240.
33. Ross JM. The pathogenesis of anthrax following the administration of spores by the respiratory route. J Pathol Bacteriol. 1957;73:485-495.
34. Glassman HN. Industrial inhalation anthrax. Bacteriol Rev. 1966;30:657-659.
35. Henderson DW, Peacock S, Belton FC. Observations on the prophylaxis of experimental pulmonary anthrax in the monkey. J Hyg. 1956;54:28-36.
36. Smith H, Keppie J. Observations on experimental anthrax. Nature. 1954;173:869-870.
37. Defense Intelligence Agency. Soviet Biological Warfare Threat. Washington, DC: US Dept of Defense; 1986. Publication DST-161OF-057-86.
38. Amramova FA, Grinberg LM, Yampolskaya O, Walker DH. Pathology of inhalational anthrax in 42 cases from the Sverdlovsk outbreak in 1979. Proc Natl Acad Sci U S A. 1993;90:2291-2294.
39. Dalldorf F, Kaufmann AF, Brachman PS. Woolsorters' disease. Arch Pathol. 1971;92:418-426.
40. Gleiser CA, Berdjis CC, Harman HA, Gochenour WS. Pathology of experimental respiratory anthrax in Macaca Mulatta. Br J Exp Pathol. 1963;44:416-426.
41. Franz DR, Jahrling PB, Friedlander A, et al. Clinical recognition and management of patients exposed to biological warfare agents. JAMA. 1997;278: 399-411.
42. Vessal K, Yeganehdoust J, Dutz W, Kohout E. Radiologic changes in inhalation anthrax. Clin Radiol. 1975;26:471-474.
43. Albrink WS, Brooks SM, Biron RE, Kopel M. Human inhalation anthrax. Am J Pathol. 1960;36:457-471.
44. Dahlgren CM, Buchanan LM, Decker HM, et al. Bacillus anthracis aerosols in goat hair processing mills. Am J Hyg. 1960;72:24-31.
45. Walker JS, Lincoln RE, Klein F. Pathophysiological and biochemical changes in anthrax. Fed Proc. 1967; 26:1539-1544.
46. Pile JC, Malone JD, Eitzen EM, Friedlander A. Anthrax as a potential biological warfare agent. Arch Intern Med. 1998;158:429-434.
47. Institute of Medicine National Research Council. Improving Civilian Medical Response to Chemical and Biological Terrorist Incidents. Washington, DC: National Academy Press; 1998:1-70.
48. Centers for Disease Control and Prevention. Bioterrorism alleging use of anthrax and interim guidelines for management - United States, 1998. MMWR Morb Mortal Wkly Rep. 1999;48:69-74.
49. Penn C, Klotz SA. Anthrax. In: Gorbach SL, Bartlett JG, Blacklow NR, eds. Infectious Diseases. Philadelphia. Pa: WB Saunders Co; 1998:1575-1578.
50. Brachman PS. Anthrax. In: Hoeprich PD, Jordan MC, Ronald AR, eds. Infectious Diseases. Philadelphia, Pa: JB Lippincott; 1994:1003-1008.
51. Anthrax vaccine, military use in Persian Gulf region [press release]. Washington, DC: US Dept of Defense; September 8, 1998.
52. Michigan Department of Public Health. Anthrax Vaccine Absorbed. Lansing: Michigan Dept of Public Health; 1978.
53. Brachman PS, Gold H, Plotkin SA, Fekety FR, Werrin M, Ingraham NR. Field evaluation of human anthrax vaccine. Am J Public Health. 1962;52:632-645.
54. Ivins BE, Fellows P, Pitt ML, et al. Efficacy of standard human anthrax vaccine against Bacillus anthracis aerosol spore challenge in rhesus monkeys. Salisbury Med Bull. 1996;87:125-126.
55. Turnbull PC. Anthrax vaccines: past, present and future. Vaccine. 1991;9:533-539.
56. Barnes JM. Penicillin and B anthracis. J Pathol Bacteriol. 1947;194:113-125.
57. Lincoln RE, Klein F, Walker JS, et al. Successful treatment of monkeys for septicemic anthrax. In: Antimicrobial Agents and Chemotherapy - 1964. Washington, DC: American Society for Microbiology; 1965: 759-763.
58. Odendaal MW, Peterson PM, de Vos V, Botha AD. The antibiotic sensitivity patterns of Bacillus anthracis isolated from the Kruger National Park. Onderstepoort J Vet Res. 1991;58:17-19.
59. Doganay M, Aydin N. Antimicrobial susceptibility of Bacillus anthracis. Scand J Infect Dis. 1991;23: 333-335.
60. American Hospital Formulary Service. AHFS Drug Information. Bethesda, Md: American Society of Health System Pharmacists; 1996.
61. Kelly D, Chulay JD, Mikesell P, Friedlander A. Serum concentrations of penicillin, doxycycline, and ciprofloxacin during prolonged therapy in rhesus monkeys. J Infect Dis. 1992;166:1184-1187.
62. Stepanov AV, Marinin LI, Pomerantsev AP, Staritsin NA. Development of novel vaccines against anthrax in man. J Biotechnol. 1996;44:155-160.
63. Schaad UB, Abdus Salam M, Aujard Y, et al. Use of fluoroquinolones in pediatrics. Pediatr Infect Dis J. 1995;14:1-9.
64. Lightfoot NF, Scott RJ, Turnbull PC. Antimicrobial susceptibility of Bacillus anthracis: proceedings of the international workshop on anthrax. Salisbury Med Bull. 1990;68:95-98.
65. Perkins WA. Public health implications of airborne infection. Bacteriol Rev. 1961;25:347-355.
66. American Public Health Association. Anthrax. In: Benenson AS, ed. Control of Communicable Diseases Manual. Washington, DC: American Public Health Association; 1995:18-22.
67. Morse S, McDade J. Recommendations for working with pathogenic bacteria. Methods Enzymol. 1994; 235:1-26.
68. Guillermin J. Anthrax: The Investigation of a Lethal Outbreak. Berkeley: University of California Press. In press.
69. Chinn KS. Reaerosolization Hazard Assessment for Biological Agent-Contaminated Hardstand Areas. Life Sciences Division, Dugway Proving Ground, Utah: US Dept of the Army; 1996:1-40. Publication DPG/JCP-96/012.
70. Resnick IG, Martin DD, Larsen LD. Evaluation of Need for Detection of Surface Biological Agent Contamination. Dugway Proving Ground, Life Sciences Division, US Dept of the Army; 1990:1-35. Publication DPG-FR-90-711.
71. Manchee RJ, Stewart WD. The decontamination of Gruinard Island. Chem Br. July 1988;690-691.
72. US Army Medical Research Institute of Infectious Diseases, Centers for Disease Control and Prevention, and US Food and Drug Administration. Medical Response to Biological Warfare and Terrorism. Gaithersburg, Md: US Army Medical Research Institute of Infectious Diseases, Centers for Disease Control and Prevention, and US Food and Drug Administration; 1998.
73. Pomerantsev AP, Staritsin NA, Mockov YV, Marinin LI. Expression of cereolysine AB genes in Bacillus anthracis vaccine strain ensures protection against experimental hemolytic anthrax infection. Vaccine. 1997;15:1846-1850.